MRNS Marinus Pharmaceuticals, Inc.

1.46
+0  (1%)
Previous Close 1.44
Open 1.45
Price To book 1.32
Market Cap 31.45M
Shares 21,542,000
Volume 197,073
Short Ratio 2.72
Av. Daily Volume 1,233,210

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
Ganaxolone
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 2 preliminary CDKL5 cohort data released January 23, 2017. Top-line data due mid-2017.
Ganaxolone
CDKL5 disorder